{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:48:16Z","timestamp":1747036096862,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20DZ1100101"],"award-info":[{"award-number":["20DZ1100101"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The widespread application of colonoscopy screening and genetic testing in colorectal cancer (CRC) treatment has led to the identification of a subset of familial adenomatous polyposis (FAP) patients who lack a family history of the disease but harbor germline gene mutations. Moreover, distinct genotypes may be associated with varied clinical presentations and therapeutic options. This case report describes a male patient with de novo FAP who harbored germline double heterozygosity (GDH) for APC and BRCA2 mutations. The patient underwent total colectomy, and genetic testing enabled personalized surveillance and management strategies for his family members.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 43-year-old male with no family history of cancer presented to the outpatient clinic of the Colorectal Surgery Department with complaints of constipation and hematochezia. Colonoscopy revealed hundreds of polyps throughout the colon and a rectal adenocarcinoma located 5\u00a0cm from the anal verge. Gastroduodenal endoscopy did not detect any upper gastrointestinal adenomas. The patient underwent laparoscopic total colectomy with abdominoperineal resection of the rectum and end ileostomy. With the consent of the patient and his family, genetic testing was performed. The index patient was found to carry an APC splicing site mutation (exon 15: c.1744-1G\u2009&gt;\u2009A) and a BRCA2 missense mutation (exon 17: c.7976G\u2009&gt;\u2009A: p.R2659K). His daughter was found to have inherited the same germline BRCA2 variant. Additionally, the rectal cancer exhibited proficient DNA mismatch repair (pMMR) status, ERBB2 copy number amplification, and a missense mutation, while the KRAS, NRAS, and BRAF genes were wild-type. Based on the genetic testing results and clinical manifestations, the index patient was diagnosed with familial adenomatous polyposis (FAP) and rectal cancer. Personalized surveillance and management strategies were implemented for the patient and his family, focusing on the risks of extra-colonic diseases and potential malignancies in the prostate, pancreas, breast, and ovaries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>De novo FAP with double germline mutations in APC and BRCA2, along with somatic ERBB2 mutations, is exceptionally rare among hereditary cancer cases. With the rapid advancements in genomics, the detection of multiple gene variants in individuals or families has become increasingly common. Additionally, the application of artificial intelligence (AI) in medical research may provide powerful tools for genetic analysis and clinical decision-making. Consequently, a comprehensive evaluation of family history, a deep understanding of hereditary cancer syndromes, and precise interpretation of genetic mutations are essential for personalized clinical management in the era of precision medicine. However, these tasks pose significant challenges for clinicians and genetic counselors alike.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13053-025-00306-x","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:02:23Z","timestamp":1740128543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["De novo familial adenomatous polyposis with germline double heterozygosity of APC\/BRCA2: a case report and literature review"],"prefix":"10.1186","volume":"23","author":[{"given":"Tian-Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Dong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"11","key":"306_CR1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jmoldx.2021.07.024","volume":"23","author":"P Rofes","year":"2021","unstructured":"Rofes P, Gonzalez S, Navarro M, Moreno-Cabrera JM, Solanes A, Darder E, Carrasco E, Iglesias S, Salinas M, Gomez C, et al. Paired somatic-germline testing of 15 polyposis and colorectal Cancer-predisposing genes highlights the role of APC mosaicism in De Novo familial adenomatous polyposis. J Mol Diagn. 2021;23(11):1452\u20139.","journal-title":"J Mol Diagn"},{"issue":"6","key":"306_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3393\/ac.2021.00878.0125","volume":"37","author":"JC Kim","year":"2021","unstructured":"Kim JC, Bodmer WF. Genotypic and phenotypic characteristics of Hereditary Colorectal Cancer. Ann Coloproctol. 2021;37(6):368\u201381.","journal-title":"Ann Coloproctol"},{"issue":"8","key":"306_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s10147-021-01881-4","volume":"26","author":"N Tomita","year":"2021","unstructured":"Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, et al. Japanese Society for Cancer of the Colon and rectum (JSCCR) guidelines 2020 for the clinical practice of Hereditary Colorectal Cancer. Int J Clin Oncol. 2021;26(8):1353\u2013419.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"306_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12881-018-0701-y","volume":"19","author":"H Giang","year":"2018","unstructured":"Giang H, Nguyen VT, Nguyen SD, Nguyen HP, Vo BT, Nguyen TM, Nguyen NH, Truong KD, Do TT, Phan MD, et al. Detection of a heterozygous germline APC mutation in a three-generation family with familial adenomatous polyposis using targeted massive parallel sequencing in Vietnam. BMC Med Genet. 2018;19(1):188.","journal-title":"BMC Med Genet"},{"key":"306_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcdb.2023.04.004","volume":"150\u2013151","author":"J Abbott","year":"2023","unstructured":"Abbott J, Nathke IS. The adenomatous polyposis coli protein 30 years on. Semin Cell Dev Biol. 2023;150\u2013151:28\u201334.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"306_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12957-023-02951-9","volume":"21","author":"M Xu","year":"2023","unstructured":"Xu M, Zheng Y, Zuo Z, Zhou Q, Deng Q, Wang J, Wang D. De novo familial adenomatous polyposis associated thyroid cancer with a c.2929delG frameshift deletion mutation in APC: a case report and literature review. World J Surg Oncol. 2023;21(1):73.","journal-title":"World J Surg Oncol"},{"issue":"5","key":"306_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1001\/jama.2012.8780","volume":"308","author":"S Grover","year":"2012","unstructured":"Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, Wenstrup RJ, Syngal S. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308(5):485\u201392.","journal-title":"JAMA"},{"issue":"11","key":"306_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s10038-023-01178-6","volume":"68","author":"R Harada","year":"2023","unstructured":"Harada R, Matsubayashi H, Kiyozumi Y, Kobayashi H, Mitsuya K, Imai K, Yamamoto Y, Oishi T, Kado N, Nishimura S, et al. A Japanese case of ovarian mucinous adenocarcinoma with germline double variants of MSH2 and BRCA2. J Hum Genet. 2023;68(11):783\u20137.","journal-title":"J Hum Genet"},{"issue":"6460","key":"306_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1126\/science.aax4588","volume":"365","author":"E Zeggini","year":"2019","unstructured":"Zeggini E, Gloyn AL, Barton AC, Wain LV. Translational genomics and precision medicine: moving from the lab to the clinic. Science. 2019;365(6460):1409\u201313.","journal-title":"Science"},{"key":"306_CR10","doi-asserted-by":"crossref","unstructured":"Madar L, Majoros V, Szucs Z, Nagy O, Babicz T, Butz H, Patocs A, Balogh I, Koczok K. Double heterozygosity for Rare deleterious variants in the BRCA1 and BRCA2 genes in a Hungarian patient with breast Cancer. Int J Mol Sci 2023, 24(20).","DOI":"10.3390\/ijms242015334"},{"issue":"2","key":"306_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-021-06095-w","volume":"186","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, Sardesai S. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series. Breast Cancer Res Treat. 2021;186(2):569\u201375.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"306_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ygyno.2019.11.019","volume":"156","author":"C Le Page","year":"2020","unstructured":"Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, et al. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: a systematic review and case report analysis. Gynecol Oncol. 2020;156(2):377\u201386.","journal-title":"Gynecol Oncol"},{"key":"306_CR13","doi-asserted-by":"publisher","first-page":"102381","DOI":"10.1016\/j.coph.2023.102381","volume":"70","author":"J Brownlie","year":"2023","unstructured":"Brownlie J, Kulkarni S, Algethami M, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Targeting DNA damage repair precision medicine strategies in cancer. Curr Opin Pharmacol. 2023;70:102381.","journal-title":"Curr Opin Pharmacol"},{"key":"306_CR14","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.","journal-title":"Mol Biol Int"},{"issue":"7407","key":"306_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330\u20137.","journal-title":"Nature"},{"key":"306_CR16","doi-asserted-by":"crossref","unstructured":"Yoshikawa A, Nakamura Y. Molecular basis of HER2-Targeted therapy for HER2-Positive colorectal Cancer. Cancers (Basel) 2022, 15(1).","DOI":"10.3390\/cancers15010183"},{"issue":"1","key":"306_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-017-4393-3","volume":"166","author":"SW Njoroge","year":"2017","unstructured":"Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1\/2 negative breast cancer patient. Breast Cancer Res Treat. 2017;166(1):315\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"306_CR18","first-page":"335","volume":"47","author":"V Zajac","year":"2000","unstructured":"Zajac V, Tomka M, Ilencikova D, Majek P, Stevurkova V, Kirchhoff T. A double germline mutations in the APC and p53 genes. Neoplasma. 2000;47(6):335\u201341.","journal-title":"Neoplasma"},{"issue":"1","key":"306_CR19","first-page":"79","volume":"21","author":"C Soravia","year":"2006","unstructured":"Soravia C, DeLozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, Foulkes WD, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. Int J Colorectal Dis. 2006;21(1):79\u201383.","journal-title":"Int J Colorectal Dis"},{"key":"306_CR20","doi-asserted-by":"publisher","first-page":"658389","DOI":"10.3389\/fonc.2021.658389","volume":"11","author":"W Huang","year":"2021","unstructured":"Huang W, Bian J, Qian X, Shao L, Li H, Zhang L, Wang L. Case Report: Coinheritance of germline mutations in APC and BRCA1 in Colorectal Cancer. Front Oncol. 2021;11:658389.","journal-title":"Front Oncol"},{"key":"306_CR21","doi-asserted-by":"crossref","unstructured":"D\u2019Elia G, Caliendo G, Casamassimi A, Cioffi M, Molinari AM, Vietri MT. APC and MUTYH analysis in FAP patients: a novel mutation in APC gene and genotype-phenotype correlation. Genes (Basel) 2018, 9(7).","DOI":"10.3390\/genes9070322"},{"issue":"2","key":"306_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1572-0241.2006.00375.x","volume":"101","author":"P Galiatsatos","year":"2006","unstructured":"Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101(2):385\u201398.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"306_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/humu.20087","volume":"24","author":"S Aretz","year":"2004","unstructured":"Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R, Moslein G, Schulmann K, Propping P, Friedl W. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum Mutat. 2004;24(5):370\u201380.","journal-title":"Hum Mutat"},{"key":"306_CR24","first-page":"95","volume":"8","author":"ML Leoz","year":"2015","unstructured":"Leoz ML, Carballal S, Moreira L, Ocana T, Balaguer F. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet. 2015;8:95\u2013107.","journal-title":"Appl Clin Genet"},{"issue":"7","key":"306_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/hmg\/10.7.721","volume":"10","author":"NS Fearnhead","year":"2001","unstructured":"Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet. 2001;10(7):721\u201333.","journal-title":"Hum Mol Genet"},{"key":"306_CR26","doi-asserted-by":"crossref","unstructured":"Disciglio V, Forte G, Fasano C, Sanese P, Lepore Signorile M, De Marco K, Grossi V, Cariola F, Simone C. APC splicing mutations leading to In-Frame exon 12 or exon 13 skipping are rare events in FAP Pathogenesis and define the clinical outcome. Genes (Basel) 2021, 12(3).","DOI":"10.3390\/genes12030353"},{"issue":"4","key":"306_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/BF03195640","volume":"49","author":"A Plawski","year":"2008","unstructured":"Plawski A, Slomski R. APC gene mutations causing familial adenomatous polyposis in Polish patients. J Appl Genet. 2008;49(4):407\u201314.","journal-title":"J Appl Genet"},{"issue":"13","key":"306_CR28","doi-asserted-by":"publisher","first-page":"21327","DOI":"10.18632\/oncotarget.15570","volume":"8","author":"D Wang","year":"2017","unstructured":"Wang D, Liang S, Zhang Z, Zhao G, Hu Y, Liang S, Zhang X, Banerjee S. A novel pathogenic splice acceptor site germline mutation in intron 14 of the APC gene in a Chinese family with familial adenomatous polyposis. Oncotarget. 2017;8(13):21327\u201335.","journal-title":"Oncotarget"},{"issue":"44","key":"306_CR29","doi-asserted-by":"publisher","first-page":"16620","DOI":"10.3748\/wjg.v20.i44.16620","volume":"20","author":"FG Campos","year":"2014","unstructured":"Campos FG. Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol. 2014;20(44):16620\u20139.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"306_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"306_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jmg.2009.075176","volume":"47","author":"DG Evans","year":"2010","unstructured":"Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. J Med Genet. 2010;47(10):710\u20131.","journal-title":"J Med Genet"},{"issue":"6","key":"306_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/carcin\/bgq069","volume":"31","author":"PJ O\u2019Donovan","year":"2010","unstructured":"O\u2019Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast\/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961\u20137.","journal-title":"Carcinogenesis"},{"issue":"1","key":"306_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.15537\/smj.2020.1.24759","volume":"41","author":"NN Junejo","year":"2020","unstructured":"Junejo NN, AlKhateeb SS. BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update. Saudi Med J. 2020;41(1):9\u201317.","journal-title":"Saudi Med J"},{"issue":"1","key":"306_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, et al. Genetic\/Familial High-Risk Assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77\u2013102.","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"306_CR35","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, Lee A, Yang X, McGuffog L, et al. Cancer risks Associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529\u201341.","journal-title":"J Clin Oncol"},{"issue":"11","key":"306_CR36","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/jnci\/djy148","volume":"110","author":"M Oh","year":"2018","unstructured":"Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I. BRCA1 and BRCA2 gene mutations and colorectal Cancer risk: systematic review and Meta-analysis. J Natl Cancer Inst. 2018;110(11):1178\u201389.","journal-title":"J Natl Cancer Inst"},{"key":"306_CR37","doi-asserted-by":"crossref","unstructured":"Shafi G, Ulle PMS, Srinivasan A, Vasudevan K, Jadhav A, Joshi V, et al. AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images. J Clin Oncol. 2022;3019\u20133019.","DOI":"10.1200\/JCO.2022.40.16_suppl.3019"},{"issue":"4","key":"306_CR38","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/2159-8290.CD-21-0090","volume":"11","author":"B Bhinder","year":"2021","unstructured":"Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discov. 2021;11(4):900\u201315.","journal-title":"Cancer Discov"},{"key":"306_CR39","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yan C, Yang Z, Zhou M, Sun J. Multi-omics deep-learning prediction of homologous recombination Deficiency-like phenotype improved risk stratification and guided therapeutic decisions in gynecological cancers. IEEE J Biomed Health Inf. 2023;1\u201311.","DOI":"10.1109\/JBHI.2023.3308440"},{"issue":"5","key":"306_CR40","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","volume":"51","author":"DC Gulhan","year":"2019","unstructured":"Gulhan DC, Lee JJ, Melloni GEM, Cortes-Ciriano I, Park PJ. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019;51(5):912\u20139.","journal-title":"Nat Genet"},{"issue":"2","key":"306_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10689-016-9952-y","volume":"16","author":"C Goehringer","year":"2017","unstructured":"Goehringer C, Sutter C, Kloor M, Gebert J, Slater EP, Keller M, Treiber I, Ganschow P, Kadmon M, Moog U. Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor. Fam Cancer. 2017;16(2):303\u20139.","journal-title":"Fam Cancer"},{"issue":"5","key":"306_CR42","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamaoncol.2021.8196","volume":"8","author":"JH Strickler","year":"2022","unstructured":"Strickler JH, Yoshino T, Graham RP, Siena S, Bekaii-Saab T. Diagnosis and treatment of ERBB2-Positive metastatic colorectal Cancer: a review. JAMA Oncol. 2022;8(5):760\u20139.","journal-title":"JAMA Oncol"},{"issue":"2","key":"306_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224\u201337.","journal-title":"Cancer Discov"},{"issue":"2","key":"306_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155\u201363.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"306_CR45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jcmgh.2021.04.012","volume":"12","author":"E Murray","year":"2021","unstructured":"Murray E, Cheng X, Krishna A, Jin X, Ohara TE, Stappenbeck TS, Bose R. HER2 and APC mutations promote altered crypt-villus morphology and marked Hyperplasia in the intestinal epithelium. Cell Mol Gastroenterol Hepatol. 2021;12(3):1105\u201320.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"306_CR46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-016-3697-z","volume":"155","author":"DG Evans","year":"2016","unstructured":"Evans DG, Lalloo F, Howell S, Verhoef S, Woodward ER, Howell A. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Res Treat. 2016;155(3):597\u2013601.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"306_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijc.30692","volume":"141","author":"GT Lang","year":"2017","unstructured":"Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, Zhuang ZG, Cao AY, Ling H, Yu KD, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer. 2017;141(1):129\u201342.","journal-title":"Int J Cancer"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-025-00306-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:00:10Z","timestamp":1740132010000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-025-00306-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1186\/s13053-025-00306-x","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"3 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved and carried out according to the ethical guidelines of Fudan University Shanghai Cancer Center (FUSCC) and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}